Get the Stockscreener App
2.48
8.15%
-0.22
After Hours:
2.52
0.04
+1.61%
Annovis Bio Inc stock is traded at $2.48, with a volume of 248.27K.
It is down -8.15% in the last 24 hours and up +1.64% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$2.70
Open:
$2.61
24h Volume:
248.27K
Relative Volume:
0.45
Market Cap:
$65.73M
Revenue:
-
Net Income/Loss:
$-30.26M
P/E Ratio:
-1.2157
EPS:
-2.04
Net Cash Flow:
$-24.69M
1W Performance:
-10.47%
1M Performance:
+1.64%
6M Performance:
+8.30%
1Y Performance:
+46.75%
1-Day Range:
$2.42
$2.665
1-Week Range:
$2.42
$2.8399
52-Week Range:
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.48 | 71.56M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Announces Two Presentations at the AD/PD 2026 International Conference - Bitget
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - The Manila Times
New Alzheimer’s and Parkinson’s trial data from Annovis headed to AD/PD 2026 - Stock Titan
AI Stocks: Will Annovis Bio Inc. benefit from rising consumer demandTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS
ANVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annovis nears FDA threshold for Alzheimer's drug as CEO eyes spring milestone - The Business Journals
Tech Rally: Whats the analyst consensus on Annovis Bio Inc2025 Buyback Activity & AI Powered Market Entry Ideas - baoquankhu1.vn
Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS
Should you avoid Annovis Bio Inc. stock right nowEarnings Recap Summary & Weekly Setup with ROI Potential - mfd.ru
Trading Action: Will Annovis Bio Inc. benefit from seasonalityJuly 2025 Weekly Recap & Technical Pattern Based Signals - mfd.ru
Is Annovis Bio Inc. a defensive stockJuly 2025 Final Week & Safe Capital Growth Trade Ideas - mfd.ru
Aug Analyst Calls: Will Annovis Bio Inc benefit from seasonalityQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Rate Hike: Can ADSE keep up with sector leadersJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
Malvern-based Annovis continues phase 3 Alzheimer’s trial after safety review - MSN
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review - MyChesCo
Will Annovis Bio Inc. stock rally after Fed decisionsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - mfd.ru
Can Annovis Bio Inc. disrupt its industryJuly 2025 Institutional & Real-Time Volume Triggers - mfd.ru
ANVS Should I Buy - Intellectia AI
Guidance Update: Will Annovis Bio Inc. stock recover after earningsJuly 2025 Highlights & Low Risk Growth Stock Ideas - mfd.ru
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod - TipRanks
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
Annovis Bio Receives Positive Safety Recommendation from DSMB for Buntanetap in Alzheimer's Phase 3 Trial - Quiver Quantitative
Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease. - Bitget
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease - ChartMill
Annovis Bio (NYSE:ANVS) Shares Down 1%Here's Why - MarketBeat
Is Annovis Bio Inc. stock forming a triangle patternJuly 2025 EndofMonth & Momentum Based Trading Ideas - mfd.ru
Is Annovis Bio Inc. part of any major indexEntry Point & Long Hold Capital Preservation Tips - mfd.ru
CEO Moves: Should you avoid Annovis Bio Inc. stock right nowJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Can Annovis Bio Inc. deliver consistent dividendsJuly 2025 Technicals & Reliable Entry Point Alerts - mfd.ru
How Annovis Bio Inc. stock performs during Fed tightening cyclesJuly 2025 News Drivers & Real-Time Stock Price Movement Reports - mfd.ru
Highs Report: Should you avoid Annovis Bio Inc stock right nowQuarterly Investment Review & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Stock Market Recap: Will Annovis Bio Inc. benefit from rising consumer demand2025 Support & Resistance & Reliable Momentum Entry Alerts - baoquankhu1.vn
Portfolio Recap: Will APA Corporation outperform its industry peersWeekly Risk Summary & High Yield Stock Recommendations - baoquankhu1.vn
Annovis Bio Hosts Regulation FD Investor Information Webinar - TipRanks
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
2026 Catalysts: Psychiatry, epilepsy and neurodegeneration - biocentury.com
Hedge Fund Bets: Will Annovis Bio Inc stock hit new highs in YEARJuly 2025 Technicals & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Aug Rallies: Is Annovis Bio Inc a defensive stockQuarterly Profit Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Published on: 2026-01-26 04:28:37 - baoquankhu1.vn
US Market Wrap: Can Annovis Bio Inc deliver consistent dividendsJuly 2025 Momentum & Capital Efficient Trading Techniques - baoquankhu1.vn
Movement Recap: What are the future prospects of XPeng Inc Depositary ReceiptWeekly Stock Analysis & Consistent Return Investment Signals - baoquankhu1.vn
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MSN
Value Recap: What are Hess Corporations earnings expectationsMarket Trend Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Outlook: Is TOMI Environmental Solutions Inc in accumulation or distribution phase2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Stop Loss: Is Annovis Bio Inc stock a smart retirement pickJuly 2025 Market Mood & Smart Swing Trading Alerts - baoquankhu1.vn
Can Annovis Bio Inc. stock surprise with earnings upside2025 Buyback Activity & Verified Chart Pattern Signals - Улправда
Key Neurology Trial Readouts to Watch in Early 2026 - NeurologyLive
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):